BioPharm International

1 week ago | biopharminternational.com | Patrick Lavery

Following the AAPS National Biotechnology Conference 2025 (AAPS Bio), BioPharm International® caught up with Austin Daniels, PhD, an application scientist for Yokogawa Fluid Imaging Technologies, who presented a poster at the event, “Using Flow Imaging Microscopy to Meet Particulate Matter Standards for Biotherapeutics.” Flow imaging microscopy is effective in this application, according to Daniels, because imaging-based methods have been generally shown to be more sensitive to translucent...

1 week ago | biopharminternational.com | Patrick Lavery

At the AAPS National Biotechnology Conference 2025 (AAPS Bio), which was held in Boston from May 4–7, 2025, Jerry Chapman, principal, Quality Data & Analytics for Redica Systems, delivered an oral presentation entitled “Using Artificial Intelligence to Evaluate Potential Clinical Study Sites.” In an interview with BioPharm International® following that session, Chapman discussed the advantages and high points of attending a conference like AAPS Bio, but also went into detail about some of the...

1 week ago | biopharminternational.com | Patrick Lavery

Pharmaceutical Technology® Group interfaced with nearly a dozen companies at the annual INTERPHEX conference in New York City on April 1 and 2, 2025, and while one of the overarching topics may have been the tariff policies of United States President Donald Trump’s administration—in which there were new developments during the event—many of the interviewees over those two days were eager to share their businesses’ latest innovations in manufacturing and how those might fit into the industry...

1 week ago | biopharminternational.com | Patrick Lavery

Biocon Biologics, a subsidiary of India-based Biocon, announced on May 25, 2025, that its biosimilar of ustekinumab, under the brand name Yesintek, was granted marketing approval by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) (1). The agent is indicated for the treatment of adults and children aged 6 and older who have moderate to severe plaque psoriasis, as well as adults with active psoriatic arthritis or moderately to severely active Crohn’s disease.

1 week ago | biopharminternational.com | Susan Haigney

The biopharma industry is seeing growth in innovation with new treatments for cancer and autoimmune diseases and the development of specialized medicines. New technologies, such as artificial intelligence and machine learning, are also having an impact on drug development and manufacturing. New drugs come with the cost to develop and produce before they can reach patients.